When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

Hims & Hers (HIMS) has launched an online GLP-1 supply tracker where people can share information about where the popular ...

MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access ...

Scientists from the University of Copenhagen say they have developed a drug that decreases appetite while increasing calorie ...

The effects last only for a few hours. Examples include exenatide and lixisenatide. Ozempic: Novo Nordisk’s name-brand ...

Better known by Novo Nordisk's brand names Ozempic and Wegovy (the former of which is indicated only for type 2 diabetes), ...

GLP-1 agonists – of which Novo Nordisk’s Ozempic and Wegovy (semaglutide) and Eli Lilly’s Mounjaro (tirzepatide) are the most ...

On a call with investors last week, Danish drugmaker Novo Nordisk shared some teasers about CagriSema, the next generation of ...

Hims & Hers is launching a tracker of GLP-1 shortages to push back against the FDA's recent moves to end compounding copycats ...

Hims & Hers Health launched a GLP-1 Supply Tracker to spotlight challenges in accessing obesity medications, addressing ...

In the case of popular medications like Ozempic and Wegovy, the drug manufacturer Novo Nordisk told Global News the company has mitigation plans to minimize any disruption.

Research, Clinical, and Policy Implications Discontinuation is a common issue for many chronic therapies, but it’s ...